title: Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor.
authors.affiliation: Dalhousie Medicine New Brunswick, Saint John. Electronic address: mariah.giberson@dal.ca.
authors.forename: Mariah
authors.initials: M
authors.lastname: Giberson
authors.affiliation: Department of Ophthalmology & Visual Sciences, Dalhousie University, Moncton, N.B.
authors.forename: Vicki
authors.initials: V
authors.lastname: Taylor
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000068258:Bevacizumab / Q000191:economics / Q000627:therapeutic use*; D017281:Cost of Illness; D016527:Drug Costs; D019538:Health Care Surveys; D006801:Humans; D058449:Intravitreal Injections / Q000706:statistics & numerical data*; D009509:New Brunswick; D009885:Ophthalmology / Q000706:statistics & numerical data*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D000069579:Ranibizumab / Q000191:economics / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence / Q000706:statistics & numerical data; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000188:drug therapy / Q000191:economics
chemical_list: D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab